Provided by Tiger Trade Technology Pte. Ltd.

Incyte

127.81
+0.59000.46%
Post-market: 127.810.00000.00%19:30 EDT
Volume:1.37M
Turnover:175.38M
Market Cap:25.91B
PE:16.28
High:129.92
Open:126.45
Low:125.60
Close:127.22
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.00
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:4.08
PE(LYR):19.94

Loading ...

Incyte Announces Positive Chmp Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

THOMSON REUTERS
·
Jun 26

Incyte (INCY) Lands Fresh Clinical Wins, Is It Fully Valued?

Simply Wall St.
·
Jun 26

UBS Adjusts Price Target on Incyte to $113 From $103

MT Newswires Live
·
Jun 25

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 25

S&P 500 Futures Rise in Premarket Trading; Dick's Sporting Goods, Zimmer Biomet Holdings Lag

Dow Jones
·
Jun 24

Incyte Price Target Maintained with a $140.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and Incyte (INCY)

TIPRANKS
·
Jun 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Pfizer (PFE)

TIPRANKS
·
Jun 23

What Incyte (INCY)'s Oncology And Rare-Disease Pipeline Milestones Mean For Shareholders

Simply Wall St.
·
Jun 23

Incyte Corp. Stock Rises 5.5%, Outperforms Peers

Dow Jones
·
Jun 23

Incyte price target raised to $105 from $103 at Truist

TIPRANKS
·
Jun 23

Truist Securities Raises Incyte Price Target to $105 From $103, Hold Rating Kept

MT Newswires Live
·
Jun 23

BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee

Reuters
·
Jun 22

BUZZ-Incyte rises as it settles Medicaid dispute with US government

Reuters
·
Jun 22

Incyte - Plans to Update Financial Guidance to Reflect Settlement Impact at Next Earnings Release - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte: Settlement Was Reached Based on the Unique Facts of Opzelura and Jakafi

THOMSON REUTERS
·
Jun 22

Incyte - CMS Will Not Apply Line Extension Regulation to Opzelura; Incyte Withdraws Lawsuit - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte - Expects One-Time Non-Cash Benefit of $246 Mln in Q2 Ending June 30, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte - Announces Agreement With CMS to Resolve Opzelura Medicaid Rebate Litigation - SEC Filing

THOMSON REUTERS
·
Jun 22